Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

GLP-1 drugs linked to dramatically lower death rates in colon cancer patients

2.

Preoperative MRI is useful for identifying additional disease in breast cancer patients with nodes positive.

3.

PFS in Multiple Myeloma Is Improved by Daratumumab Added to Standard Therapy.

4.

TULSA Is Effective in Long-Term Prostate Cancer Control.

5.

Rising rates of head and neck cancers in England


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot